SMMT Summit Therapeutics Inc.
Price Chart
Executive Summary
Summit Therapeutics disclosed that its Audit Committee and independent directors approved company affiliates to purchase shares under the existing ATM facility with JP Morgan. Separately, CEO Robert Duggan, Co-CEO Mahkam Zanganeh, and COO/CFO Manmeet Soni indicated they are likely to purchase shares in the near term, but no binding commitments or share amounts were provided.
Actionable Insight
The non-binding insider buying indications are a modest positive signal of management alignment, but lack of commitment and share amounts limits conviction. Monitor for actual insider purchases via Form 4 filings to gauge conviction. The ATM remains available for company affiliate use, which could create modest dilution over time.
Key Facts
- Audit Committee and independent directors approved company affiliates to purchase shares under the ATM with JP Morgan.
- CEO Robert Duggan, Co-CEO Mahkam Zanganeh, and COO/CFO Manmeet Soni indicated they are likely to purchase shares under the ATM in the near term.
- No number of shares or binding commitments were disclosed for insider purchases.
- Any insider purchases would be at prevailing market bid price or better.
- The ATM was previously disclosed; this filing provides an update on potential insider participation.
Financial Impact
No dollar amounts or share counts disclosed; potential insider buying at market prices could signal alignment but is non-binding.
Risk Factors
- Insider purchase indications are non-binding and may not materialize.
- ATM share sales by company affiliates could dilute existing shareholders.
- No financial data or guidance provided to assess fundamental outlook.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000049 |
| Document: 0001599298-26-000049-index-headers.html | 0001599298-26-000049 |
| Document: 0001599298-26-000049-index.html | 0001599298-26-000049 |
| Document: 0001599298-26-000049.txt | 0001599298-26-000049 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Insider Cluster
| $13.60 awaiting T+1 | awaiting T+1 | — | $14.01 (+3.05%) |
|
Jun 12, 2026
today
|
Institutional Cluster
| $13.08 awaiting T+1 | awaiting T+1 | — | $14.01 (+7.15%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.03 awaiting T+1 | awaiting T+1 | — | $14.01 (+7.52%) |
|
Jun 9, 2026
3d ago
|
S-3ASR
| $14.29 awaiting T+1 | awaiting T+1 | — | $14.01 (+1.93%) |
|
Jun 4, 2026
8d ago
|
Insider Cluster
| $15.01 awaiting T+1 | awaiting T+1 | — | $14.01 (−6.66%) |
|
Jun 4, 2026
8d ago
|
Insider Cluster
| $15.30 awaiting T+1 | awaiting T+1 | — | $14.01 (−8.43%) |
|
Jun 3, 2026
9d ago
|
8-K
| $15.07 $14.84 | ▼ −1.53% | ▼ −1.93% | $14.01 (−7.03%) |
|
Jun 1, 2026
11d ago
|
8-K
| $15.71 $14.86 | ▼ −5.41% | ▼ −5.56% | $14.01 (−10.82%) |
|
Apr 30, 2026
6w ago
|
8-K
| $16.12 $16.98 | ▲ +5.37% | ▲ +5.71% | $14.01 (−13.06%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $25.12 $26.38 | ▲ +5.02% | ▲ +5.67% | $14.01 (−44.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access